Your Search Returned 500 tagged news reports
We're having a hard enough time existing at the whim of accountant CEOs and now we have ex industry scientists and a Cambridge professor trying to knock a few more nails in our coffin. Permalink to Comment Anonymous on June 13, 2014 11:05 AM writes.
This post originally appeared on the Shareaholic blog and is republished with permission. As a blogger, I've done (and still do) silly things and have learned hard lessons from those embarrassing experiences. Throughout my career, I've written
The insurance companies and Medicare need bargain hard to bring Gilead to its knees...Permalink to Comment Anonymous on May 29, 2014 9:49 AM writes... Perhaps a better comparison is with the cost of the previous (less effective, longer duratiuon and
But this paper in Organic Process R&D manages to get away with it in a preparation of a fluoronaphthyridine...Entries 5 and 6 in Table 1 (page F in the article) caught my eye: #: time, startingmaterial/product/by-products 5: 10 hours, 0/100/0 6: 27
Permalink to Comment Kelvin Stott on April 8, 2014 10:51 AM writes... Very concerning indeed, but on a positive note, this is a great example of how an institution can lay down the foundation of how to test drugs in animal models the right way, which
Reference lists are much longer (which surely reflects both the sie of the literature and the relative ease of bibliography compared to the bound-volume/index card days). Francois-Xavier Coudert, the blog's author, says that he'll be putting up some
Next Ian will be seeking more innovation....just CEO speak without specifics Permalink to Comment good point on February 20, 2014 10:16 AM writes... that is long time due. Permalink to Comment good point on February 20, 2014 10:16 AM writes... that
Permalink to Comment Anonymous on February 13, 2014 11:26 AM writes... You are incredibly restrained when you write these posts, Derek. I occasionally comment on your blog about the need for change in this industry. The big pharma model is dead in
Puff the Mutant Dragon on January 23, 2014 11:54 AM writes.....Permalink to Comment Anonymous on January 23, 2014 12:31 PM writes.....As a chemical biologist, I'd be wary of using anything with more than a single lesion, and it seems to me that the
I love these fake soul-searching moments, having witnessed several of them firsthand when I was at Lilly. The financial rewards to prescriber payola and off-label marketing are so strong that public shaming and/or legal crackdowns are the only hope.